The patent covers the following: "Such potential

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2 My69z #141958
720
The patent covers the following:
"Such potential applications include diseases with an inflammatory component namely, respiratory tract infections (RSV, SARS), neuroinflammation (WNV, HSV, CMV), liver infections (HCV), asthma, autoimmunity (MS, Lupus, liver disease, psoriasis, Crohn's Disease, Inflammatory bowel disease, etc.), atherosclerosis, angiogenesis and cancer (prostrate, breast, melanoma, gastric, colon, ovarian, etc.), fibrosis and transplant rejection and GvHD. Methods and compounds of the present invention may also be used in connection with transplantation including GvHD, autoimmunity (MS, Lupus, Psoriasis, autoimmune liver disease, etc.), inflammation in respiratory viral diseases (RSV, SARS), other viral diseases (HCV, CMV, WNV), infectious agents, cancer applications for angiogenesis and unlocking Treg suppression of antitumor CTLs, and atherosclerosis and fibrosis. As indicated here, the interaction between the CCL5 ligand and the CCR5 receptor is implicated in several disease states."

NSAIDS are written to reduce inflammation. When a doctor appreciates some form of inflammation, he might decide to write an NSAID like celebrex or meloxicam. However, there are forms of inflammation that NSAIDS do not address. Sometimes the synovial swelling that occurs in Rheumatoid conditions is so severe, that even DMARDs cannot reduce.

What about after a round of steroids, all of a sudden a patient finds themselves with another disease they never knew they had. Why is that? Because the prednisone reduced their immune system to allow a whole new disease to envelop them and they become inflammed. In such cases, it becomes a no brainer to bring in leronlimab to normalize the balance of T cells and CCR5 receptors which is what happens in long covid treated with leronlimab.

What implications could that point to? Immunosuppression is common in many disorders, especially cancer and diabetes. Especially those who require chemotherapy. Chemotherapy acts like a poison. What do you think that does to someone's immune system? Their entire immune system, both Innate and Adaptive are both probably dead from the chemo itself. All white blood cell lines fatigued to the point of exhaustion trying to fight off the chemo. How low do you think the CCR5 count is in chemo patients? Probably zero. Many elderly too are immunosuppressed. Somehow, they are unable to mount the appropriate response when they become infected. Could they have low CCR5 levels as they age? Diabetics who have difficulty with glucose control tend to be immunosuppressed. Could higher sugar levels have an effect on CCR5 surface expression? And what about those who require long stents of and large doses of prednisone and cortisone. Their immune systems are suppressed. Could cortisone itself interact with CCR5 and disable it? Many auto-immune patients see rheumatologists are prescribed cortisone and other anti-inflammatory medications, many of which are called DMARDs which are Disease Modifying Anti-Rheumatic Drugs. These medications suppress select portions of the immune system so the patient no longer suffers from diseases which attack the person him/herself, which are auto-immune disorders.

Convergence

Quote:
"I see this first partner as a BP who may be sort of "disliked" by the rest of the BP group. Maybe, their medications are running close to the end of patent. Maybe, their medications are not as functional as the latest and greatest. Maybe favor and chances have been given unfairly to other BP groups who have learned to play the bribery game.

Yet, it remains strong. It plans a Take over, by planning its bases.

It plans to Join, with the strategic alliances. To Join, with the waterfront areas. Leronlimab is the jack of all trades and it excels on each indication, exceedingly well. It is not just the master of one indication. It is the master of many an indication while also being the jack of them all. This BP who requires CytoDyn's courtship, pursues CytoDyn for the assistance that Leronlimab affords them in their plight to win success in their war against MASH, HIV, mTNBC and mColo-Rectal Cancer.

GSK has a new Chief Scientific Advisor Tony Wood who favors CCR5 antagonists as he has invented Maraviroc and he knows the power of the CCR5 antagonist mechanism of action.

My suspicion once Amarex arbitration settles is that Sidley Austin becomes CytoDyn's enforcement. The Partnerships that will be set up and enacted need to be delt with and controlled to prevent infiltrations. With an enforcer present, this will be kept at bay.

CytoDyn shall require an internal coordinator. Could our future include a non-Pharm entity like Sidley Austin? Sidley Austin currently are the premier attorneys in defense against fraudulent business practices. CytoDyn has the premier jack of all trades, master of many indication monoclonal antibody. There is a ton of news out there. You can find it yourself, as to what is happening to CytoDyn and Leronlimab. Because of Leronlimab's excellent diversity and usefulness, CytoDyn is and will continue to be pushed and pressured from all sides, to be able to maintain any form of presence in the Big Pharma world. Yet, this is exactly where CytoDyn belongs, as the premier play in HIV, NASH and oncology with the use of this brilliant CCR5 blockade. The two companies could help each other out big time if they would play their cards right. This has to play itself out, and I have my fingers crossed, but am skeptical."

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 34

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 55

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 183

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 67

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 147

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 0

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 65

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading

Top 5 Most Recently Viewed Articles

First Advantage to Engage Investors at Wolfe FinTech Forum

Updated Category News Views 219

First Advantage to Engage Investors at Wolfe FinTech Forum ATLANTA, March 04, 2025 — First Advantage Corporation (NASDAQ: FA), renowned as a premier provider in employment background screening, identity verification, and other related solutions, is set to showcase its offerings at an upcoming pivotal event. Management of First Advantage will participate in a fireside...

Continue Reading
European Markets Open Strong: EV Collaborations Boost Sentiment

Updated Category News Views 140

European Markets Show Positive Trends European stock markets are beginning the week on a high note, reflecting a cautiously optimistic mood among investors. The overall sentiment is driven by various factors that are currently in play within the financial landscape. The DAX in Germany has risen by 0.4%, while France's CAC 40 has increased by 0.7%. In contrast, the FTSE...

Continue Reading
Southern Company Stock Reaches New Heights, Driven by Growth

Updated Category News Views 81

Southern Company Achieves Record Stock Price Southern Company (NYSE: SO) has recently celebrated a remarkable achievement with its stock price hitting a record high of $91.87. This surge marks an impressive 36.84% increase over the past year, showcasing a growing optimism among investors in the energy sector. The company has been proactive in expanding its operations...

Continue Reading
Exploring GDP Trends: Navigating Economic Uncertainties

Updated Category News Views 337

Understanding Recent GDP Trends The latest economic indicators reveal complexities that question the idea of a resilient economy. Despite these challenges, we remain optimistic for the time being. Let's take a closer look at the current situation: GDP Growth Rate Adjustments The Atlanta Fed’s GDPNow tracking model recently revised its estimated growth rate for the first...

Continue Reading
Live Nation's Ticket Sales Surge Amid Mixed Earnings Report

Updated Category News Views 347

Overview of Live Nation's Recent Performance Live Nation Entertainment, Inc. (NYSE: LYV) witnessed a notable decline in its stock price after the announcement of third-quarter earnings that did not meet market expectations. Despite the drop, the company reported impressive ticket sales and revenue growth. Financial Highlights The entertainment giant reported a substantial...

Continue Reading